RESEARCH TRIANGLE PARK, N.C. — Worldwide Clinical Trials, a global clinical research organization, has appointed John Capicchioni as Senior Vice President, Commercial, Early Phase. In this role, he will oversee business development and commercial strategy for the company’s Early Phase business unit, which includes the Bioanalytical Center of Excellence in Austin, Texas, and the Clinical Pharmacology Unit in San Antonio, Texas.
Worldwide’s Early Phase organization specializes in first-in-human studies, clinical pharmacology, and bioanalysis for both small and large molecules. Its 200-bed clinical pharmacology unit supports flexible, customized Phase I research, while its bioanalytical laboratory provides advanced technology and rapid turnaround for pharmacokinetic and pharmacodynamic analysis. These capabilities are designed to accelerate early development timelines and support data-driven decision-making.
“We’re delighted to welcome John to our team,” said Mike Mencer, Executive Vice President and General Manager, Early Phase. “His extensive industry experience and proven track record of driving sales performance and revenue growth make him an ideal fit for this critical role. We’re confident that his leadership will help advance our Early Phase business and strengthen our position in the market.”
Capicchioni brings more than 20 years of business development experience in the life sciences sector. He has previously held senior roles at PPD (Thermo Fisher Scientific), Cliantha Research, and MDS Pharma Services, where he led commercial teams, expanded service offerings, and delivered sustained revenue growth.
“I am thrilled to join Worldwide Clinical Trials and lead Early Phase commercial operations at such a pivotal time for the organization,” said Capicchioni. “Worldwide’s commitment to excellence in bioanalytical and clinical services aligns strongly with my passion for advancing scientific research through strategic leadership and operational precision. I look forward to supporting continued growth and delivering meaningful value to our clients.” (Source: IANS)
